Bispecific antibodies are an emerging class of novel immunotherapy agents that have led to major breakthroughs in treating hematologic malignancies—and have promising applications for solid tumors. Learn about the mechanism of bispecific antibodies, discover existing and emerging therapies, and hear about the administration of the first FDA-approved bispecific antibody for the treatment of malignancy, including challenges and opportunities.

Testing for measurable residual disease can shape treatment choices and affect overall outcomes for patients with B-cell acute lymphoblastic leukemia. Unfortunately, routine MRD testing is variable. This three-part webinar series is aimed at building capacity to implement, expand, and sustain MRD testing for patients with adult B-cell ALL at cancer programs and practices of all resource levels.

The COVID-19 pandemic has affected treatment patterns for patients with CLL. Javier Munoz, MD, MS, FACP, Senior Associate Consultant in the Division of Hematology and Medical Oncology at the Mayo Clinic (Arizona) will discuss considerations for treating patients with CLL in the pandemic--including options for treatment, best timing for treatment, and any changes to the usual treatment regimen. Dr. Munoz will also explore what care may look like for patients with CLL beyond COVID-19.

The COVID-19 pandemic has heightened the distress patients with CLL are experiencing and taken its toll on providers. In this presentation, Alison Mayer Sachs, MSW, LSW, OSW-C, FAOSW, Director of Community Outreach & Cancer Support Services in the Eisenhower Lucy Curci Cancer Center at Eisenhower Medical Center will discuss the distress experienced by both patients and providers and offer solutions and ways forward.

The speaker will discuss considerations around the COVID-19 vaccines and interpret the respective NCCN guidance for patients with CLL and other cancers.

Panelists will discuss considerations for resuming pre-pandemic level visits and procedures for patients with CLL, Acute , and Multiple Myeloma. Panelists will also discuss their wins and challenges with providing care to respective patients in a pandemic.

Learn more about the role of laboratory medicine professionals and pathologists, including a review of testing techniques and applications as well as lab-specific regulations and their impact on biomarker testing.

Hear finding and experiences of ACCC member programs who successfully orchestrated a quality improvement project to expand BRCA testing for eligible patients with breast cancer.

The David King Community Clinical Scientist Award recognizes individuals who have demonstrated leadership in the development, participation, and evaluation of clinical studies and/or are active in the development of new screening, risk assessment, treatment, or supportive care programs for cancer patients.

The Clinical Research Award recognizes individuals whose research has significantly and positively impacted the oncology patient, family, and/or community.